U.S. Business Inventories Edged Higher in February
By Joshua Kirby
U.S. businesses added to their inventories in February, a sign that consumers aren't being deterred from spending despite stubbornly high price inflation.
Business inventories rose by 0.4% over the month after staying flat at the beginning of the year, adjusted Commerce Department figures showed Monday. This was in line with the expectations of economists polled by The Wall Street Journal.
Inventories climbed at all types of business, rising 0.6% on month at retailers, 0.5% at wholesalers and 0.3% at manufacturers. On an annual basis, total inventories were 1.0% higher.
The ratio of inventories to sales, a guide to how many months it would take for businesses to clear their inventories at the current sales rate, fell slightly to 1.38 in February from 1.39 a month earlier. The ratio was 1.37 in February of last year.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
April 15, 2024 10:27 ET (14:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track